Allarity Therapeutics (NASDAQ:ALLR) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Allarity Therapeutics (NASDAQ:ALLR) released its quarterly earnings data on Friday, May 15th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.05, Zacks reports. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million.

Allarity Therapeutics Stock Performance

ALLR opened at $1.43 on Monday. Allarity Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.35. The stock has a market capitalization of $22.75 million, a price-to-earnings ratio of -1.99 and a beta of 0.52. The business has a 50 day moving average of $1.47 and a 200-day moving average of $1.22.

Hedge Funds Weigh In On Allarity Therapeutics

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its position in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after buying an additional 16,729 shares during the last quarter. Jane Street Group LLC acquired a new stake in Allarity Therapeutics during the second quarter worth about $27,000. XTX Topco Ltd acquired a new stake in Allarity Therapeutics during the fourth quarter worth about $36,000. Citadel Advisors LLC bought a new position in Allarity Therapeutics during the third quarter valued at about $149,000. Finally, DRW Securities LLC bought a new position in Allarity Therapeutics during the fourth quarter valued at about $133,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Allarity Therapeutics to a “hold” rating in a report on Saturday, May 30th. Finally, Ascendiant Capital Markets lifted their price objective on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the company a “buy” rating in a research note on Monday, June 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $10.25.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.